Please check your internet connection and try again.
# Miconazole Vaginal Pessary
## Overview
Miconazole is an imidazole antifungal agent. The vaginal pessary formulation is intended for localized treatment of vaginal yeast infections.
## Primary Indications
Treatment of vulvovaginal candidiasis (yeast infection).
## Adult Dosing
* **100 mg vaginal pessary:** Insert 1 pessary vaginally at bedtime for 7 consecutive days.
* **200 mg vaginal pessary:** Insert 1 pessary vaginally at bedtime for 3 consecutive days.
* **Single-dose vaginal suppository (1200 mg):** Insert 1 suppository vaginally at bedtime.
The specific regimen depends on the product available and prescriber preference.
## Pediatric Dosing
Safety and efficacy in pediatric patients have not been established. Use in pediatric patients is generally not recommended unless deemed essential by a clinician, and under close medical supervision.
## Dose Adjustments
No dose adjustments are typically necessary for renal or hepatic impairment with the vaginal pessary formulation due to minimal systemic absorption.
## Contraindications
* Known hypersensitivity to miconazole or any component of the formulation.
## Adverse Effects
* **Common:** Vaginal burning, itching, irritation, redness, cramping.
* **Less Common:** Headache, rash.
## Key Drug Interactions
* **Warfarin:** Miconazole can inhibit CYP2C9, potentially increasing warfarin levels and bleeding risk. Monitor INR closely if co-administered, although the risk is significantly lower with vaginal formulations compared to oral or intravenous miconazole.
* **CYP3A4 Substrates:** Theoretical risk of increased levels of drugs metabolized by CYP3A4 (e.g., certain calcium channel blockers, statins, benzodiazepines). However, systemic absorption from vaginal pessaries is minimal, making this interaction unlikely to be clinically significant.
## Monitoring
* Monitor for signs and symptoms of vaginal candidiasis.
* Monitor for and manage any local irritation or allergic reactions.
## Clinical Pearls
* Advise patients to complete the full course of therapy, even if symptoms improve.
* Avoid intercourse during treatment to prevent partner exposure and potential reinfection, though the risk is low.
* The pessary may weaken latex condoms and diaphragms; alternative contraceptive methods should be used during treatment and for at least 72 hours after completion.
* If symptoms persist after the course of treatment, re-evaluation is necessary to confirm diagnosis and consider alternative therapies.
***
*Disclaimer: This information is intended for healthcare professionals. It is essential to consult the official prescribing information and current clinical guidelines for the most up-to-date and comprehensive details before making any treatment decisions.*
